Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.56 |
| ▸ | ABL1 | P00519 | 14/20 | 0.56 |
| ▸ | HCK | P08631 | 9/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.52 |
| ▸ | EGFR | P00533 | 8/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.52 |
| ▸ | MTOR | P42345 | 8/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 8/20 | 0.52 |
| ▸ | PRKDC | P78527 | 8/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886192 | 0.93 | SRC (0.57) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613627 | 0.90 | SRC (0.59) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613742 | 0.88 | SRC (0.60) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613702 | 0.86 | SRC (0.71) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16886136 | 0.85 | SRC (0.55) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL16769955 | 0.85 | KDR (0.66) | SRCABL1PIK3CDEGFRKDR | |
| SCHEMBL15613658 | 0.83 | SRC (0.50) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613783 | 0.82 | BTK (0.49) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL15613584 | 0.82 | BTK (0.38) | SRCABL1HCKPIK3CDEGFR | |
| SCHEMBL19490550 | 0.81 | SRC (0.48) | SRCABL1HCKPIK3CDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-9796716-B2 | Selective inhibitors of Tec and Src protein kinase families | PHARMASCIENCE, INC. (CA) | 2017-10-24 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2015-07-09 | — | — | US | disclosed |
| WO-2013177668-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE, INC. (CA) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191473-A1 | PROTEIN KINASE INHIBITORS | TEC, SRC, LCK | SRC 2/4885ABL1 4/4885HCK 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.